Please login to the form below

Not currently logged in
Email:
Password:

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Shire offloads oncology unit to Servier for $2.4bn

Shire offloads oncology unit to Servier for $2.4bn

Shire has agreed to sell its cancer drugs business to French drugmaker Servier for $2.4bn, even as it prepared for a possible takeover offer from Takeda. ... The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase)

Latest news

  • AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

    AstraZeneca’s PD-L1 inhibitor Imfinzi and Bavarian Nordic’s cancer vaccine CV301 will be combined in a phase I/II trial involving patients with metastatic colorectal or pancreatic cancers. ... Colorectal and pancreatic cancers are among the most

  • Merck forges closer ties with Cancer Research UK Merck forges closer ties with Cancer Research UK

    Merck forges closer ties with Cancer Research UK. Will partake in three research projects covering hit discovery to preclinical candidate selection. ... notable pipeline failures, including evofosfamide for advanced soft tissue sarcoma and pancreatic

  • Prospects for Lilly’s Verzenio hit by botched lung cancer trial Prospects for Lilly’s Verzenio hit by botched lung cancer trial

    it has “several studies ongoing of rational combinations that include abemaciclib in non-small cell lung cancer and other malignancies”. ... It is nevertheless a setback to Lilly’s plans to develop the drug for specific tumour mutations such as KRAS

  • The conundrum of screening The conundrum of screening

    Scenarios in which early screening makes very little difference are diseases like ovarian and pancreatic cancer. ... Everything from cancer screenings to preventive medications like folic acid for the prevention of neural tube defects.

  • Celgene joins PD-1 race via partnership with BeiGene Celgene joins PD-1 race via partnership with BeiGene

    The deal for the drug - which is in late-stage trials in cancer and has been tested in around 500 patients to date - gives haematological cancer specialist Celgene a bigger pipeline ... BeiGene is also acquiring Celgene's commercial operations in Asia

More from news
Approximately 22 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Accelerating innovation Accelerating innovation

    Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from Merrimack’s Onivyde. ... Much like its work in liver cancer with Cabometyx, being active in pancreatic cancer allows it to compete in

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

  • Pharma deals during September 2014 Pharma deals during September 2014

    Baxter is licensing Merrimack's nanoliposomal injection of irinotecan which has orphan status in the US and the EU for metastatic pancreatic cancer, but does not have US rights.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    One such example within pancreatic cancer demonstrates how it might be advantageous to take a more strategic outlook on recruitment centres. ... 7) EpiomicTM Patient Segmentation Database, Pancreatic Adenocarcinoma Disease Sub-Population, Pancreatic

  • Porterhouse Medical Group charity round-up for 2017

    Other disease awareness and fund-raising activities were carried out throughout the year for World Cancer Day, MPS Awareness Day, Jeans for Genes Day and World Pancreatic Cancer Day.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics